DUBLIN--(BUSINESS WIRE)--The "Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Renal Failure in the United States, EU5, and Japan.
Acute Renal Failure Drug Chapters:
This segment of the Acute Renal Failure report encloses the detailed analysis of marketed drugs and late stage pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are large windows of opportunity for Acute Kidney Injury (AKI): to prevent AKI, to treat AKI after its onset, and to halt progression to ESRD. The pharmaceutical industry is investing on clinical trials conducted in the cardiovascular space, yet is little reluctant to enter the kidney market as the overall market is driven by monitoring system followed by transplantation with a very small therapeutic window. Detailed chapter for upcoming therapies EA-230 (Exponential Biotherapies), Zemiglo (LG Life Sciences), RESCAP (Alloksys), BB3 (Angion Biomedica), QPI-1002 (Quark) and recAP (AM Pharma) have been covered in the report.
Acute Renal Failure Market Outlook:
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Companies Mentioned
- Quark Pharma
- AM Pharma
- Angion Biomedica
- LG Life Sciences
- Alloksys
- Exponential Biotherapeutics
Key Topics Covered:
1. Key Insights
2. Acute Renal Failure Market Overview at a Glance
3. Disease Background and Overview: Acute Renal Failure (ARF)
4. Epidemiology and Patient Population
5. Epidemiology of Acute Renal Failure
6. United States
7. EU5
8. Japan
9. Treatment and Prevention
10. Global Pipeline Products
11. Emerging Therapies (Phase III Drugs)
12. 7MM Market Size of Acute Renal Failure
13. 7MM Market Share by Emerging Therapies
14. 7MM Market Share by Countries
15. 7MM Patient Share by Therapies
16. Trends Observed in the cost of Therapies in Acute Renal Failure
17. Market Drivers
18. Market Barriers
19. Capabilities
20. Appendix
21. Report Methodology
22. Disclaimer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9bg9vl/acute_renal?w=4
